Ultragenyx Pharmaceutical Inc. (RARE) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $24.79 (+0.38%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 12, 2026 | Joseph Schwartz | Leerink Partners | $60.00 | +142.1% |
| Feb 18, 2026 | Gavin Clark-Gartner | Evercore ISI | $34.00 | +37.2% |
| Feb 17, 2026 | Raghuram Selvaraju | H.C. Wainwright | $50.00 | +101.7% |
| Jan 8, 2026 | Maxwell Skor | Morgan Stanley | $50.00 | +101.7% |
| Dec 30, 2025 | Ben Burnett | Wells Fargo | $45.00 | +81.6% |
| Dec 29, 2025 | Joel Beatty | Robert W. Baird | $47.00 | +89.6% |
| Dec 29, 2025 | Jeffrey Hung | Morgan Stanley | $55.00 | +121.9% |
| Nov 24, 2025 | Gena Wang | Barclays | $50.00 | +101.7% |
| Nov 6, 2024 | Ed Arce | H.C. Wainwright | $95.00 | +283.3% |
| Nov 6, 2024 | Joseph Schwartz | Leerink Partners | $85.00 | +242.9% |
| Jun 6, 2024 | Salveen Richter | Goldman Sachs | $67.00 | +170.3% |
| May 31, 2024 | Dae Gon Ha | Stifel Nicolaus | $127.00 | +412.4% |
| May 31, 2024 | Christopher Raymond | Raymond James | $135.00 | +444.7% |
| May 31, 2024 | Joel Beatty | Robert W. Baird | $72.00 | +190.5% |
| May 31, 2024 | Whitney Ijem | Canaccord Genuity | $111.00 | +347.9% |
| Apr 15, 2024 | Dae Gon Ha | Stifel Nicolaus | $124.00 | +400.3% |
| Apr 15, 2024 | Christopher Raymond | Raymond James | $130.00 | +424.5% |
| Jul 28, 2022 | Christopher Raymond | Piper Sandler | $130.00 | +424.5% |
| May 18, 2022 | Christopher Raymond | Piper Sandler | $135.00 | +444.7% |
| Jan 10, 2022 | Yaron Werber | Cowen & Co. | $124.00 | +400.3% |
Top Analysts Covering RARE
RARE vs Sector & Market
| Metric | RARE | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | — | 2.24 | 2.41 |
| Analyst Count | — | 8 | 18 |
| Target Upside | +107.8% | +1150.1% | +14.9% |
| P/E Ratio | -4.26 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $174M | $181M | $186M | 11 |
| 2026-09-30 | $164M | $182M | $192M | 8 |
| 2026-12-31 | $199M | $220M | $233M | 5 |
| 2027-03-31 | $184M | $204M | $216M | 5 |
| 2027-06-30 | $212M | $235M | $248M | 6 |
| 2027-09-30 | $227M | $252M | $266M | 9 |
| 2027-12-31 | $299M | $332M | $351M | 5 |
| 2028-12-31 | $1.27B | $1.28B | $1.28B | 13 |
| 2029-12-31 | $1.44B | $1.77B | $2.41B | 12 |
| 2030-12-31 | $1.88B | $2.30B | $3.13B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-1.34 | $-1.22 | $-1.12 | 9 |
| 2026-09-30 | $-1.12 | $-1.05 | $-0.91 | 3 |
| 2026-12-31 | $-0.81 | $-0.76 | $-0.66 | 7 |
| 2027-03-31 | $-0.62 | $-0.58 | $-0.51 | 3 |
| 2027-06-30 | $-0.25 | $-0.23 | $-0.20 | 3 |
| 2027-09-30 | $-0.05 | $-0.05 | $-0.04 | 4 |
| 2027-12-31 | $0.58 | $0.66 | $0.71 | 3 |
| 2028-12-31 | $-2.45 | $0.66 | $2.88 | 12 |
| 2029-12-31 | $2.49 | $3.27 | $4.80 | 10 |
| 2030-12-31 | $4.39 | $5.76 | $8.47 | 5 |
Frequently Asked Questions
What is the analyst consensus for RARE?
The consensus among 0 analysts covering Ultragenyx Pharmaceutical Inc. (RARE) is — with an average price target of $49.90.
What is the highest price target for RARE?
The highest price target for RARE is $170.00, set by Christopher Raymond at Piper Sandler on 2021-09-27.
What is the lowest price target for RARE?
The lowest price target for RARE is $34.00, set by Gavin Clark-Gartner at Evercore ISI on 2026-02-18.
How many analysts cover RARE?
0 analysts have issued ratings for Ultragenyx Pharmaceutical Inc. in the past 12 months.
Is RARE a buy or sell right now?
Based on 0 analyst ratings, RARE has a consensus rating of — with a +107.8% upside to the consensus target of $49.90.
What are the earnings estimates for RARE?
Analysts estimate RARE will report EPS of $-1.22 for the period ending 2026-06-30, with revenue estimated at $181M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.